中德临床肿瘤学杂志（英文版）2009，Vol.8Issue(5)：276-278,3.DOI:10.1007/s10330-009-0028-4
多西他赛联合沙利度胺治疗激素非依赖性晚期前列腺癌的临床观察
Clinical research on treatment of advanced androgen independent prostate cancer with Docetaxel and Thalidomide
Jing Tian 1Donghai Teng 2Xiangdong Shu 1Hong Lu 1Hui Chen 1Peng Guo3
作者信息
- 1. Department of Oncology, The People's Hospital of Leshan, Leshan 614000, China
- 2. Department of Urology, The People's Hospital of Leshan, Leshan 614000, China
- 3. Chengdu Friendship Hospital, Chengdu 610041, China
- 折叠
摘要
Abstract
Objective:To evaluate the clinical effects and adverse reactions of Docetaxel and Thalidomide in treating ad-vanced androgen independent prostate cancer (AIPC). Methods:12 cases of advanced AIPC were given a combined treat-ment of Docataxel and Thalidomide, with Docetaxel 75 mg/m2 on day 1 and Thalidomide 100 mg per day as initial dose and 300 mg as terminal dose by an increase of 50 mg every week. Results:The post-treatment values of prostate specific antigen (PSA) were normal (< 4 ng/L) in 10 patients, less than 50% of pretreatment value in one patient, and no significant change in one patient. The median survival time was 14 months and period of the median symptoms reduction was 16.3 months. Com-mon adverse reactions were tolerable, including nausea, vomiting, leukopenia, anemia and thrombocytopenia. Conclusion:The regimen of Docetaxel combined with Thalidomide was effective and tolerable in the treatment of advanced AIPC.关键词
Docetaxel/Thalidomide/androgen independent prostate cancer (AIPC)/prostate specific antigen (PSA)Key words
Docetaxel/Thalidomide/androgen independent prostate cancer (AIPC)/prostate specific antigen (PSA)分类
医药卫生引用本文复制引用
Jing Tian,Donghai Teng,Xiangdong Shu,Hong Lu,Hui Chen,Peng Guo..多西他赛联合沙利度胺治疗激素非依赖性晚期前列腺癌的临床观察[J].中德临床肿瘤学杂志（英文版）,2009,8(5):276-278,3.
